

Refine Search

Search Results -

Terms	Documents
L5 and L4	0

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L8



Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, March 27, 2007
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L8</u>	L5 and l4	0	<u>L8</u>
-----------	-----------	---	-----------

DB=PGPB; PLUR=YES; OP=OR

<u>L7</u>	L6 and l4	0	<u>L7</u>
-----------	-----------	---	-----------

<u>L6</u>	DU.in.	1032	<u>L6</u>
-----------	--------	------	-----------

DB=USPT; PLUR=YES; OP=OR

<u>L5</u>	DU.in.	2350	<u>L5</u>
-----------	--------	------	-----------

<u>L4</u>	L3 and (intracellular)	16	<u>L4</u>
-----------	------------------------	----	-----------

<u>L3</u>	L2 and (composition)	45	<u>L3</u>
-----------	----------------------	----	-----------

<u>L2</u>	L1 and polypeptide	47	<u>L2</u>
-----------	--------------------	----	-----------

<u>L1</u>	omi	1579	<u>L1</u>
-----------	-----	------	-----------

END OF SEARCH HISTORY

Hit List

First Hit

Search Results - Record(s) 1 through 10 of 16 returned.

☐ 1. Document ID: US 7132523 B2

L4: Entry 1 of 16

File: USPT

Nov 7, 2006

US-PAT-NO: 7132523

DOCUMENT-IDENTIFIER: US 7132523 B2

TITLE: Human PRSS11-Like S2 serine protease and uses thereof

DATE-ISSUED: November 7, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20050019777 A1

January 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Darrow; Andrew Lawrence	Lansdale	PA		US
Qi; Jian-shen	Branchburg	NJ		US
Chen; Cailin	New Hope	PA		US
Andrade-Gordon; Patricia	Doylestown	PA		US

US-CL-CURRENT: 536/23.2; 435/226, 435/252.3, 435/252.33, 435/254.2, 435/320.1,
435/325, 435/348

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 2. Document ID: US 7125541 B2

L4: Entry 2 of 16

File: USPT

Oct 24, 2006

US-PAT-NO: 7125541

DOCUMENT-IDENTIFIER: US 7125541 B2

TITLE: Combined methods for tumor vasculature targeting and tumor treatment with radiotherapy

DATE-ISSUED: October 24, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20020037289 A1

March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		US
Burrows; Francis J.	San Diego	CA		US

US-CL-CURRENT: 424/1.49; 424/142.1, 424/155.1, 424/156.1, 424/178.1, 424/181.1,
424/183.1, 530/387.1, 530/388.15, 530/388.22, 530/388.8, 530/391.3, 530/391.7,
530/391.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 7112317 B2

L4: Entry 3 of 16

File: USPT

Sep 26, 2006

US-PAT-NO: 7112317

DOCUMENT-IDENTIFIER: US 7112317 B2

TITLE: Combined methods and compositions for tumor vasculature targeting and tumor treatment

DATE-ISSUED: September 26, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030185832 A1	October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		US
Burrows; Francis J.	San Diego	CA		US

US-CL-CURRENT: 424/1.49; 424/142.1, 424/155.1, 424/156.1, 424/178.1, 424/181.1,
424/183.1, 530/387.1, 530/388.15, 530/388.22, 530/388.8, 530/391.3, 530/391.7,
530/391.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 7067274 B2

L4: Entry 4 of 16

File: USPT

Jun 27, 2006

US-PAT-NO: 7067274

DOCUMENT-IDENTIFIER: US 7067274 B2

TITLE: Compositions and methods for the screening pro-apoptotic compounds

DATE-ISSUED: June 27, 2006

PRIOR-PUBLICATION:

DOC-ID DATE
US 20050214802 A1 September 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fairbrother; Wayne J.	Burlingame	CA		US
Franklin; Matthew C.	San Francisco	CA		US
Ackerly Wallweber; Heidi Jenii	La Honda	CA		US
Elliott; Linda Orren	Half Moon Bay	CA		US
Kadkhodayan; Saloumeh	Castro Valley	CA		US
Vucic; Domagoj	San Francisco	CA		US
Salvesen; Guy	Encinitas	CA		US

US-CL-CURRENT: [435/23](#); [435/6](#), [435/7.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Da
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 7005276 B1

L4: Entry 5 of 16

File: USPT

Feb 28, 2006

US-PAT-NO: 7005276

DOCUMENT-IDENTIFIER: US 7005276 B1

TITLE: Nucleic acid molecules correlated with the Rhesus weak D phenotype

DATE-ISSUED: February 28, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Flegel; Willy A.	Dieburg			DE
Wagner; Franz F.	Ulm			DE

US-CL-CURRENT: [435/69.1](#); [435/252.3](#), [435/320.1](#), [435/810](#), [536/23.1](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Da
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 6673908 B1

L4: Entry 6 of 16

File: USPT

Jan 6, 2004

US-PAT-NO: 6673908

DOCUMENT-IDENTIFIER: US 6673908 B1

TITLE: Tumor necrosis factor receptor 2

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stanton, Jr.; Vincent P.	Belmont	MA		

US-CL-CURRENT: 536/22.1; 435/6, 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 6489136 B1

L4: Entry 7 of 16

File: USPT

Dec 3, 2002

US-PAT-NO: 6489136

DOCUMENT-IDENTIFIER: US 6489136 B1

**** See image for Certificate of Correction ****

TITLE: Cell proliferation related genes

DATE-ISSUED: December 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zervos; Antonis S.	Woburn	MA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/252.33, 435/254.11, 435/320.1, 435/325, 435/410, 536/23.5, 536/24.3, 536/24.31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 6451312 B1

L4: Entry 8 of 16

File: USPT

Sep 17, 2002

US-PAT-NO: 6451312

DOCUMENT-IDENTIFIER: US 6451312 B1

**** See image for Certificate of Correction ****

TITLE: VEGF-gelonin for targeting the vasculature of solid tumors

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		

US-CL-CURRENT: 424/183.1; 424/185.1, 424/192.1, 530/399

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 6261535 B1

L4: Entry 9 of 16

File: USPT

Jul 17, 2001

US-PAT-NO: 6261535

DOCUMENT-IDENTIFIER: US 6261535 B1

**** See image for Certificate of Correction ****

TITLE: Diagnostic methods for targeting the vasculature of solid tumors

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Burrows; Francis J.	San Diego	CA		

US-CL-CURRENT: 424/1.49; 424/130.1, 424/133.1, 424/142.1, 424/145.1, 424/155.1,
424/156.1, 424/178.1, 424/179.1, 424/181.1, 424/183.1, 424/186.1, 424/9.32,
424/9.323, 424/9.34, 424/9.341, 424/9.36, 424/9.42, 530/387.1 , 530/388.1,
530/388.15, 530/388.22, 530/391.3, 530/391.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 10. Document ID: US 6051230 A

L4: Entry 10 of 16

File: USPT

Apr 18, 2000

US-PAT-NO: 6051230

DOCUMENT-IDENTIFIER: US 6051230 A

**** See image for Certificate of Correction ****TITLE: Compositions for targeting the vasculature of solid tumors

DATE-ISSUED: April 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Burrows; Francis J.	San Diego	CA		

US-CL-CURRENT: 424/178.1; 424/179.1, 424/180.1, 424/181.1, 424/182.1, 424/183.1,
530/387.1, 530/387.7, 530/388.1, 530/388.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L3 and (intracellular)	16
------------------------	----

Display Format:

CIT

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/Caplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/Caplus patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/Caplus accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/Caplus enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/Caplus updated with revised CAS roles
NEWS 13 JAN 22 CA/Caplus enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:53:40 ON 27 MAR 2007

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 14:54:01 ON 27 MAR 2007

FILE 'USPATFULL' ENTERED AT 14:54:01 ON 27 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:54:01 ON 27 MAR 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 14:54:01 ON 27 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:54:01 ON 27 MAR 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 14:54:01 ON 27 MAR 2007
COPYRIGHT (C) 2007 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 14:54:01 ON 27 MAR 2007
COPYRIGHT (C) 2007 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 14:54:01 ON 27 MAR 2007
Copyright (c) 2007 The Thomson Corporation

=> s omi
L1 3202 OMI

=> s IAP and cleavage
L2 1108 IAP AND CLEAVAGE

=> s (IAP polypeptide cleavage)
L3 0 (IAP POLYPEPTIDE CLEAVAGE)

=> s l2 and l1
L4 44 L2 AND L1

=> s l4 and variant
L5 18 L4 AND VARIANT

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 18 USPATFULL on STN
TI Compositions and methods for the augmentation and repair of defects in tissue
AB Compositions and methods of treating a defect in a patient are disclosed, including expanding a culture of autologous cells in vitro to form cultured cells, collecting the cultured cells for introduction into the patient, and depositing the cultured cells with ancillary proteins.

ACCESSION NUMBER: 2007:75065 USPATFULL
TITLE: Compositions and methods for the augmentation and repair of defects in tissue
INVENTOR(S): Kleinsek, Donald A., Elkhart Lake, WI, UNITED STATES
Soto, Adriana, Elkhart Lake, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007065415	A1	20070322
APPLICATION INFO.:	US 2005-229237	A1	20050916 (11)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PATTERSON, THUENTE, SKAAR & CHRISTENSEN, P.A., 4800 IDS CENTER, 80 SOUTH 8TH STREET, MINNEAPOLIS, MN, 55402-2100, US		
NUMBER OF CLAIMS:	51		
EXEMPLARY CLAIM:	1		
LINE COUNT:	8165		

L5 ANSWER 2 OF 18 USPATFULL on STN
 TI Compositions and methods for screening pro-apoptotic compounds
 AB The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:288483 USPATFULL
 TITLE: Compositions and methods for screening pro-apoptotic compounds
 INVENTOR(S): Fairbrother, Wayne J., Burlingame, CA, UNITED STATES
 Franklin, Matthew C., San Francisco, CA, UNITED STATES
 Wallweber, Heidi Jenii Ackerly, La Honda, CA, UNITED STATES
 Elliott, Linda Orren, Half Moon Bay, CA, UNITED STATES
 Kadkhodayan, Saloumeh, Castro Valley, CA, UNITED STATES
 Vucic, Domagoj, San Francisco, CA, UNITED STATES
 Sallvesen, Guy, Encinitas, CA, UNITED STATES
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
 The Burnham Institute, Encinitas, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006246471	A1	20061102
APPLICATION INFO.:	US 2005-299139	A1	20051209 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-983495, filed on 8 Nov 2004, GRANTED, Pat. No. US 7067274		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-519863P	20031113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	4017	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 18 USPATFULL on STN
 TI Use of apoptosis inhibiting compounds in degenerative neurological disorders
 AB The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In

particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:247149 USPATFULL
TITLE: Use of apoptosis inhibiting compounds in degenerative neurological disorders
INVENTOR(S): Kaplitt, Michael, New York, NY, UNITED STATES
Moussatov, Serguei, New York, NY, UNITED STATES
PATENT ASSIGNEE(S): NEUROLOGIX, INC., Floral Park, NY, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006210538	A1	20060921
APPLICATION INFO.:	US 2005-255637	A1	20051021 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-621307P	20041022 (60)
	US 2005-686588P	20050602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604, US	
NUMBER OF CLAIMS:	73	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	5472	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 18 USPATFULL on STN

TI Atherosclerotic phenotype determinative genes and methods for using the same

AB Genes whose expression is correlated with and determinant of an atherosclerotic phenotype are provided. Genes whose expression is correlated with and determinant of an atherosclerotic susceptibility are also provided. Also provided are methods of using the subject atherosclerotic determinant genes or the atherosclerotic susceptibility genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using at least one parameter that is not expression level and is preferably determined using a binary prediction tree analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:166987 USPATFULL
TITLE: Atherosclerotic phenotype determinative genes and methods for using the same
INVENTOR(S): West, Mike, Durham, NC, UNITED STATES
Nevins, Joseph R., Chapel Hill, NC, UNITED STATES
Goldschmidt, Pascal, Chapel Hill, NC, UNITED STATES
Seo, David, Durham, NC, UNITED STATES
PATENT ASSIGNEE(S): Duke University Office of Science and Technology, Durham, NC, UNITED STATES, 27750 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006141493	A1	20060629
APPLICATION INFO.:	US 2005-198782	A1	20050804 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-291885, filed
on 12 Nov 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337709P	20011109 (60)
	US 2002-374547P	20020423 (60)
	US 2002-420784P	20021024 (60)
	US 2002-421043P	20021025 (60)
	US 2002-424680P	20021108 (60)
	US 2004-651462P	20040804 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	13825	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 5 OF 18 USPATFULL on STN
TI Mitochondrial biology expression arrays
AB This invention provides a library of genes involved in mitochondrial biology, arrays containing probes for genes involved in mitochondrial biology, methods for making such arrays, and methods of using such arrays. Genes and probe sequences involved in mitochondrial biology in humans and mice are provided. The arrays of this invention are useful for determining mitochondrial biology gene expression profiles. Mitochondrial biology gene expression profiles are useful for determining expression profiles diagnostic of physiological conditions; diagnosing physiological conditions; identifying biochemical pathways, genes, and mutations involved in physiological conditions; identify therapeutic agents useful for preventing and/or treating such physiological conditions; evaluating and/or monitoring the efficacy of such therapies, and creating and identifying animal models of human physiologic conditions. Arrays containing probes for all genes known to be involved in mitochondrial biology are provided, as well as arrays containing subsets of such probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:117736 USPATFULL
TITLE: Mitochondrial biology expression arrays
INVENTOR(S): Wallace, Douglas C, Irvine, CA, UNITED STATES
Levy, Shawn, Brentwood, TN, UNITED STATES
Kerstann, Keith, Atlanta, GA, UNITED STATES
Procaccio, Vincent, Irvine, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006099578	A1	20060511
APPLICATION INFO.:	US 2002-488619	A1	20020830 (10)
	WO 2002-US27886		20020830
			20041109 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60316323	20010830
	CA 2001-2356540	20010831
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE WINNER AND SULLIVAN P C, 4875 PEARL EAST CIRCLE, SUITE 200, BOULDER, CO, 80301, US	
NUMBER OF CLAIMS:	20	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 10305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 18 USPATFULL on STN

TI Peptides and methods for cell death regulation
AB The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:68008 USPATFULL
TITLE: Peptides and methods for cell death regulation
INVENTOR(S): Steller, Hermann, New York, NY, UNITED STATES
Ryoo, Hyung Don, New York, NY, UNITED STATES
Ciechanover, Aaron, Haifa, ISRAEL
Gonen, Hedva, Zichron-Yakov, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006058229	A1	20060316
APPLICATION INFO.:	US 2003-513465	A1	20030508 (10)
	WO 2003-US12125		20030508
			20050719 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60378668	20020509
	US 2002-60448869	20020224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Eitan Pearl Latzer & Cohen Zedek, Suite 1001, 10 Rockefeller Plaza, New York, NY, 10020, US	
NUMBER OF CLAIMS:	63	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	2570	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 18 USPATFULL on STN

TI Peptides and methods for cell death regulation
AB The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid

consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:4481 USPATFULL
TITLE: Peptides and methods for cell death regulation
INVENTOR(S): Steller, Hermann, New York, NY, UNITED STATES
Ryoo, Hyung Don, New York, NY, UNITED STATES
Ciechanover, Aaron, Haifa, ISRAEL
Gonen, Hedva, Zichron-Yakov, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006003939	A1	20060105
APPLICATION INFO.:	US 2003-431638	A1	20030508 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-378668P	20020509 (60)
	US 2003-448869P	20030224 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EITAN, PEARL, LATZER & COHEN ZEDEK LLP, 10 ROCKEFELLER PLAZA, SUITE 1001, NEW YORK, NY, 10020, US	
NUMBER OF CLAIMS:	77	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	2629	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 18 USPATFULL on STN
TI Compositions and methods for the screening pro-apoptotic compounds
AB The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:247607 USPATFULL
TITLE: Compositions and methods for the screening pro-apoptotic compounds
INVENTOR(S): Fairbrother, Wayne J., Burlingame, CA, UNITED STATES
Franklin, Matthew C., San Francisco, CA, UNITED STATES
Ackerly Wallweber, Heidi Jenii, La Honda, CA, UNITED STATES
Elliott, Linda Orren, Half Moon Bay, CA, UNITED STATES
Kadkhodayan, Saloumeh, Castro Valley, CA, UNITED STATES
Vucic, Domagoj, San Francisco, CA, UNITED STATES
Salvesen, Guy, Encinitas, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
The Burnham Institute, Encinitas, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005214802	A1	20050929
	US 7067274	B2	20060627
APPLICATION INFO.:	US 2004-983495	A1	20041108 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-519863P	20031113 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA,
94080, US
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 4036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 18 USPATFULL on STN

TI Methods and compositions relating to modulating amyloid precursor
protein cleavage
AB The invention relates in part assays for identifying and testing
compounds that modulate cleavage of amyloid precursor protein
(APP). In addition, the invention relates to novel cleavage
products of APP. The invention additionally relates to methods and
assays for identifying compounds that inhibit acyl-coenzyme
A:cholesterol acyltransferase (ACAT) activity. The methods and products
of the invention are useful for identifying compounds to prevent and/or
treat APP-cleavage associated disorders (e.g. Alzheimer's
disease) and are also useful for identifying compounds to prevent and/or
treat ACAT-associated disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:196295 USPATFULL
TITLE: Methods and compositions relating to modulating amyloid
precursor protein cleavage
INVENTOR(S): Puglielli, Luigi, Madison, WI, UNITED STATES
Huttunen, Henri J., Boston, MA, UNITED STATES
Guenette, Suzanne Y., Medford, MA, UNITED STATES
Tanzi, Rudolph E., Hull, MA, UNITED STATES
Kovacs, Dora M., Charlestown, MA, UNITED STATES
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, UNITED
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005170437	A1	20050804
APPLICATION INFO.:	US 2004-984017	A1	20041108 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-518355P	20031107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MaryDilys S. Anderson, Ph.D., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210-2206, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2490	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 18 USPATFULL on STN

TI Cell-killing molecules and methods of use thereof
AB The invention provides compositions comprising amino acid sequences that
have cell killing activity, nucleic acid sequences encoding them,
antibodies that specifically bind with them, and methods of using these
compositions for increasing and/or reducing cell death, detecting cell
death, diagnosing diseases associated with altered cell death, and
methods for identifying test agents that alter cell death.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:247248 USPATFULL

TITLE: Cell-killing molecules and methods of use thereof
INVENTOR(S): Wright, Susan C., Saratoga, CA, UNITED STATES
Larrick, James W., Woodside, CA, UNITED STATES
Wilson, David S., Mountain View, CA, UNITED STATES
Nock, Steffen R., Redwood City, CA, UNITED STATES
PATENT ASSIGNEE(S): Palo Alto Institute of Molecular Medicine (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004191843	A1	20040930
APPLICATION INFO.:	US 2004-770668	A1	20040202 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-444191P	20030203 (60)
	US 2003-460855P	20030408 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	7872	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 18 USPATFULL on STN
TI Method and compounds for inhibition of cell death
AB The invention is directed to methods and compositions for inhibiting caspase-independent apoptosis. In particular, methods and compositions for inhibiting Omi/HtrA2 activity, as well as method for identifying other inhibitors of Omi/HtrA2. Also disclosed are Omi/HtrA2 specific substrates and methods for identifying other substrates of Omi/HtrA2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:221857 USPATFULL
TITLE: Method and compounds for inhibition of cell death
INVENTOR(S): Zervos, Antonis, Oviedo, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171629	A1	20040902
APPLICATION INFO.:	US 2003-728056	A1	20031204 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-369311, filed on 20 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361902P	20020228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	2165	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 18 USPATFULL on STN
TI Compositions and methods for enhancing apoptosis
AB The present invention is directed to compositions of matter useful for

the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:221783 USPATFULL
TITLE: Compositions and methods for enhancing apoptosis
INVENTOR(S): Deshayes, Kurt, San Francisco, CA, UNITED STATES
Fairbrother, Wayne, Burlingame, CA, UNITED STATES
Flygare, John, Burlingame, CA, UNITED STATES
Franklin, Matthew C., San Francisco, CA, UNITED STATES
Fischer, Saloumeh, Casto Valley, CA, UNITED STATES
Vucic, Domagoj, San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171554	A1	20040902
APPLICATION INFO.:	US 2003-364645	A1	20030207 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	2998		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 18 USPATFULL on STN
TI Compositions and methods for cleaving IAP
AB The present invention relates to compositions and methods for making and using Omi-related and IAP-cleaving nucleotide sequences, mutant nucleotide sequences, and polypeptide sequences expressed therefrom, including both biologically active and inactive molecules. The present invention relates to cleaving IAP using an Omi polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:221336 USPATFULL
TITLE: Compositions and methods for cleaving IAP
INVENTOR(S): Du, Chunying, Leawood, KS, UNITED STATES
Yang, Qiheng, Kansas City, KS, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171105	A1	20040902
	US 2005233411	A9	20051020
APPLICATION INFO.:	US 2003-730476	A1	20031208 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-445508P	20030207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	POLSINELLI SHALTON WELTE SUELTHAUS P.C., 700 W. 47TH STREET, SUITE 1000, KANSAS CITY, MO, 64112-1802	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Page(s)	
LINE COUNT:	4866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 18 USPATFULL on STN
TI Methods and compositions for treating hematological disorders using 131,

148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules

AB The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306020 USPATFULL

TITLE: Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules

INVENTOR(S): Carroll, Joseph M., Cambridge, MA, UNITED STATES
Healy, Aileen, Medford, MA, UNITED STATES
Weich, Nadine S., Brookline, MA, UNITED STATES
Kelly, Louise M., Brookline, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215452	A1	20031120
APPLICATION INFO.:	US 2003-352684	A1	20030128 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-354333P	20020204 (60)
	US 2002-360258P	20020228 (60)
	US 2002-364476P	20020315 (60)
	US 2002-375626P	20020426 (60)
	US 2002-386494P	20020606 (60)
	US 2002-390965P	20020624 (60)
	US 2002-392480P	20020628 (60)
	US 2002-394128P	20020703 (60)
	US 2002-399783P	20020731 (60)
	US 2002-403221P	20020813 (60)
	US 2002-407045P	20020830 (60)
	US 2002-429048P	20021125 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

LINE COUNT: 11102

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 18 USPATFULL on STN

TI Methods and reagents for peptide-BIR interaction screens

AB The invention features a substantially pure polypeptide having a length

of less than 100 amino acids and capable of forming a complex with a polypeptide that includes a BIR domain. The invention also features displacement assays in which the ability of a candidate compound to disrupt the interaction between a BIR domain-containing polypeptide and a polypeptide of the invention is indicative of the ability of the candidate compound to modulate IAP biological activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:225710 USPATFULL
 TITLE: Methods and reagents for peptide-BIR interaction screens
 INVENTOR(S): Boudreault, Alain, Montreal, CANADA
 Korneluk, Robert G., Ottawa, CANADA
 LaCasse, Eric, Ottawa, CANADA
 Liston, Peter, Ottawa, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157522	A1	20030821
APPLICATION INFO.:	US 2002-293371	A1	20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-332300P	20011109 (60)
	US 2002-370934P	20020408 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	1624	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 18 USPATFULL on STN

TI Omi and domains thereof that disrupt IAP-caspase interaction

AB An isolated nucleic acid molecule comprising a polynucleotide having a sequence encoding a peptide or polypeptide of Omi having at least an N-terminus amino acid sequence of Ala-Val-Pro-Ser and up to 321 contiguous amino acid residues that can be derived from residues 138-458 of SEQ ID NO:1 or a functional variant of each, each of which is capable of specifically binding to at least a portion of an Inhibitor of Apoptosis protein. This peptide can be used in a method to modulate apoptosis or to identify modulators of apoptosis as well as in therapeutic uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106717 USPATFULL
 TITLE: Omi and domains thereof that disrupt IAP-caspase interaction
 INVENTOR(S): Alnemri, Emad S., Ambler, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073629	A1	20030417
APPLICATION INFO.:	US 2002-197634	A1	20020715 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-340163P	20011214 (60)
	US 2001-305378P	20010713 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 75
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 18 USPATFULL on STN

TI Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for
mediating apoptosis
AB The invention provides caspase-9-related peptides and polypeptides
capable of binding to an Inhibitor of Apoptosis Protein (IAP),
as well as caspase-9 mutant that fail to undergo normal processing and
fail to bind to an IAP. Nucleic acid molecules, including
expression vectors, encoding such peptides and polypeptides are also
provided. Such peptides and polypeptides, are useful for inducing
apoptosis and identifying inhibitors and enhancer of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:288105 USPATFULL
TITLE: Conserved XIAP-interaction motif in caspase-9 and
Smac/DIABLO for mediating apoptosis
INVENTOR(S): Alnemri, Emad S., Ambler, PA, UNITED STATES
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, UNITED
STATES, 19107 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160975	A1	20021031
APPLICATION INFO.:	US 2002-68569	A1	20020206 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-939293, filed on 24 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-267966P	20010208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	94	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	3217	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 18 OF 18 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

TI New Omi nucleic acids and peptides that bind to an inhibitor of
apoptosis proteins, useful for regulating or altering caspase-mediated
apoptosis and for treating cancer, tumor, or autoimmune diseases
AN 2003-221760 [21] WPIDS
AB WO 2003006680 A2 UPAB: 20050528
NOVELTY - An isolated nucleic acid molecule (I) comprising a
polynucleotide encoding an Omi peptide or polypeptide having:
(a) a sequence of 4-7 amino acids, and up to 321 contiguous amino
acid residues derived from residues 138-458 of a defined sequence of 458
amino acids (II) that specifically binds to a portion of an Inhibitor of
Apoptosis Protein (IAP); or
(b) a sequence amino acid residues 134-458 of (II) except that the
serine at position 306 is mutated.
DETAILED DESCRIPTION - An isolated nucleic acid molecule (I)

comprising a polynucleotide encoding an Omi peptide or polypeptide having:

(a) a sequence of 4-7 amino acids, and up to 321 contiguous amino acid residues derived from residues 138-458 of a defined sequence of 458 amino acids (II) that specifically binds to a portion of an Inhibitor of Apoptosis Protein (IAP); or

(b) a sequence amino acid residues 134-458 of (II) except that the serine at position 306 is mutated.

The Omi polypeptide induces caspase-independent apoptosis, or fails to have serine protease activity. INDEPENDENT CLAIMS are also included for:

(1) an expression vector comprising (I) operatively linked to regulatory elements;

(2) a host cell containing the expression vector;

(3) an isolated peptide or polypeptide comprising 4 amino acids up to 321 contiguous amino acid residues derived from residues 138-458 of (II) that specifically binds to a portion of an IAP;

(4) an isolated Omi polypeptide comprising:

(a) 4-7 amino acids up to 314 or 321 contiguous amino acid residues derived from residues 138-458 of (II), where the polypeptide induces caspase-independent apoptosis or fails to have serine protease activity; or

(b) a sequence of amino acid residues 134-458 of (II) except that the serine at position 306 is mutated and the polypeptide fails to have serine protease activity;

(5) a method for inducing caspase-dependent apoptosis in a cell comprises contacting the cell with (I) or with an Omi peptide or polypeptide;

(6) methods of identifying an inhibitor or enhancer of caspase-mediated apoptosis;

(7) a method for identifying a compound that inhibits Omi binding to an Omi-binding molecule;

(8) a method for identifying a compound that inhibits Omi binding to a portion of an IAP;

(9) a method for identifying a compound that inhibits Omi binding to a Omi-binding molecule that is not an IAP;

(10) an antibody that specifically binds to a peptide or polypeptide above;

(11) an antibody that specifically binds to an epitope located on the N-terminus of Omi;

(12) a composition comprising (I), a peptide or antibody defined above, and a physiological carrier;

(13) an isolated nucleic acid molecule comprising a polynucleotide having a sequence encoding a functional variant of the Omi peptide or polypeptide defined above, where the variant has at least 50% identity of the peptide, or at least 75% or 85% identity of the polypeptide up to 75 residues in length, and specifically binds to a portion of an IAP;

(14) a method of producing a compound for inhibiting or enhancing apoptosis, particularly caspase-dependent apoptosis in a cell; and

(15) a process for manufacturing a compound for inhibiting or enhancing apoptosis, particularly caspase-dependent apoptosis in a cell.

ACTIVITY - Cytostatic; Immunosuppressive; Neuroprotective; Vasotropic.

No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The Omi peptides are useful for regulating or altering apoptosis, specifically caspase-mediated apoptosis, and as immunogens for raising antibodies. Enhancers of apoptosis are useful for treating cancers, tumors or for destroying cells that mediate autoimmune diseases. Compositions may also be used for the treatment of diseases associated with inappropriate activation of apoptosis such as neurodegenerative diseases and ischemic injury. The antibodies can be used in isolating Omi peptides, polypeptides and their variants, in

identifying molecules that interact with Omi peptides and polypeptides, and in inhibiting or enhancing the biological activity of Omi peptides and polypeptides. MCF-7 and HeLa cells were transfected with full-length antisense Omi cDNA in pRSC-GFP double expression vector or an empty pRSC-GFP (-), to reduce the expression of Omi in the transfected cells. Seventy-two hours after transfection, cells were treated with Fas (500 ng/ml, 5 hours), TRAIL (1 micrograms/ml, 5 hours) or staurosporine (1 micrograms, 5 hours). The percentages of GFP-positive apoptotic cells were determined by fluorescent microscopy after staining with DAPI and propidium iodide. The Omi antisense cDNA reduced significantly (30-35%) the sensitivity of the transfected cells to apoptotic stimuli, indicating that Omi participates together with other apoptotic factors in the overall sensitivity of cells to apoptosis.

ACCESSION NUMBER: 2003-221760 [21] WPIDS
 DOC. NO. CPI: C2003-056527 [21]
 TITLE: New Omi nucleic acids and peptides that bind to an inhibitor of apoptosis proteins, useful for regulating or altering caspase-mediated apoptosis and for treating cancer, tumor, or autoimmune diseases
 DERWENT CLASS: B04; D16
 INVENTOR: ALNEMRI E S
 PATENT ASSIGNEE: (ALNE-I) ALNEMRI E S; (UYJE-N) UNIV JEFFERSON THOMAS
 COUNTRY COUNT: 98

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003006680	A2	20030123	(200321)*	EN	42	[25]
US 20030073629	A1	20030417	(200329)	EN		
AU 2002320574	A1	20030129	(200452)	EN		
AU 2002320574	A8	20051103	(200629)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003006680	A2	WO 2002-US22658	20020715
US 20030073629	A1 Provisional	US 2001-305378P	20010713
US 20030073629	A1 Provisional	US 2001-340163P	20011214
AU 2002320574	A1	AU 2002-320574	20020715
US 20030073629	A1	US 2002-197634	20020715
AU 2002320574	A8	AU 2002-320574	20020715

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002320574	A1 Based on	WO 2003006680 A
AU 2002320574	A8 Based on	WO 2003006680 A

PRIORITY APPLN. INFO: US 2001-340163P 20011214
 US 2001-305378P 20010713
 US 2002-197634 20020715